Traffic:
10E
10W
15N
15S
57N
57S
60E
60W
210E
210W
This Site
Web Search
powered by
YAHOO! SEARCH
Subscriber Services
|
Home Delivery
|
e-Edition
|
Alerts
|
RSS
Home
News
Ontario
Rancho Cucamonga
Pomona
Upland
Claremont
Montclair
Chino Valley
California
Crime & Public Safety
Elections
Education
S.B. County Watch
Upland Watch
I.E.: Medicare Testing Ground
Sports
Buy Event Tickets Now
Golf - Tee Times and Courses
Preps
Reign Hockey
Rancho Cucamonga Quakes
Local Colleges
USC
UCLA
Lakers
Clippers
Dodgers
Angels
Ducks
Soccer
Motor Sports
Horse Racing
Live Odds
Business
Autos
Real Estate News
Technology
Opinions
Editorial
Letters
Columnists
Blogs
LA.COM
Buy Tickets
Movies
TV
Music
Shopping & Beauty
Recreation
Neighborhood
Arts
Living
Dining
Find A Restaurant
Lottery
Horoscopes
Travel
Trevor's Travels
Health
Crossword Puzzle
Local Casinos
Foothills Magazine
Info
Subscribe For Home Delivery
Contact Us
RSS
Podcast
Subscriber Services
Place An Ad
NIE
Classified
Place an Ad
Homes
Jobs
Auto
Search autos
Buy/Sell a car
Research/Financing a car
Find a dealer
Shopping
This week's ads
Obits
Directories
Local Business
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sangamo Therapeutics
(NQ:
SGMO
)
0.9207
-0.0150 (-1.60%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sangamo Therapeutics
< Previous
1
2
3
4
5
6
Next >
12 Health Care Stocks Moving In Monday's Intraday Session
February 12, 2024
Via
Benzinga
Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease
February 12, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Why Palantir Technologies Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
February 06, 2024
Shares of Palantir Technologies Inc. (NYSE: PLTR) rose sharply during today’s pre-market trading after the company reported better-than-expected fourth-quarter sales results and issued guidance.
Via
Benzinga
Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
February 05, 2024
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Deep Dive Into Sangamo Therapeutics Stock: Analyst Perspectives (4 Ratings)
January 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
January 19, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 10, 2024
Via
Benzinga
2 low-priced gene therapy stocks to speculate on
January 08, 2024
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe
Via
MarketBeat
Exposures
Product Safety
Where Sangamo Therapeutics Stands With Analysts
November 06, 2023
Via
Benzinga
What 8 Analyst Ratings Have To Say About Sangamo Therapeutics
November 06, 2023
Via
Benzinga
Analyst Ratings for Sangamo Therapeutics
August 15, 2023
Via
Benzinga
A Preview Of Sangamo Therapeutics's Earnings
August 07, 2023
Via
Benzinga
Why Shapeways Holdings Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
November 15, 2023
Shares of Shapeways Holdings, Inc. (NASDAQ: SHPW) tumbled during Wednesday’s session following downbeat results.
Via
Benzinga
What To Know About RBC Capital's Downgrade of Sangamo Therapeutics
November 03, 2023
Via
Benzinga
Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
November 01, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
November 02, 2023
Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholders.
Via
Benzinga
Earnings Scheduled For November 1, 2023
November 01, 2023
Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of $9.37 billion.
Via
Benzinga
Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
October 25, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics to Present Pre-Clinical Data Showcasing Its Epigenetic Regulation for Neurology and CAR-Treg Research at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)
October 24, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
September 20, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
August 31, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
October 05, 2023
On Thursday, 369 companies hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
September 26, 2023
On Tuesday, 386 stocks made new 52-week lows.
Via
Benzinga
Why NovoCure Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
August 28, 2023
Gainers Mobile Infrastructure Corporation (NASDAQ: BEEP) shares jumped 98.7% to $12.02.
Via
Benzinga
Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases
August 25, 2023
Treating rare diseases is a tough but potentially lucrative business. With clinical trials coming due, here are three stocks to buy.
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
August 18, 2023
We're starting the final day of trading this week with a dive into the biggest pre-market stock movers worth watching for Friday!
Via
InvestorPlace
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
August 08, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Announces Second Quarter 2023 Conference Call and Webcast
August 01, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics and Chroma Medicine Announce Option and License Agreement to Evaluate and Develop Zinc Finger Proteins for Epigenetic Editing
July 20, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
Sangamo Therapeutics Announces Research Evaluation and Option Agreement With Prevail, a Wholly Owned Subsidiary of Lilly, for Novel Engineered Capsids
July 17, 2023
From
Sangamo Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Privacy Policy
|
Terms of Use
|
MNG Corporate Site Map
|
Copyright